Percutaneous Mitral Valve Repair in Cancer Patients with Heart Failure and Severe Mitral Regurgitation

Zahi Abu Ghosh*, Mony Shuvy, Ronen Beeri, Israel Gotsman, Batla Falah, Mahsati Ibrahimli, Dan Gilon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Cancer patients with heart failure (HF) and severe mitral regurgitation (MR) are often considered to be at risk for surgical mitral valve repair/replacement. Severe MR inducing symptomatic HF may prevent delivery of potentially cardiotoxic chemotherapy and complicate fluid management with other cancer treatments. Objectives: To evaluate the outcome of percutaneous mitral valve repair (PMVR) in oncology patients with HF and significant MR. Methods: Our study comprised 145 patients who underwent PMVR, MitraClip, at Hadassah Medical Center between August 2015 and September 2019, including 28 patients who had active or history of cancer. Data from 28 cancer patients were compared to 117 no-cancer patients from the cohort. Results: There was no significant difference in the mean age of cancer patients and no-cancer patients (76 vs. 80 years, P = 0.16); 67% of the patients had secondary (functional) MR. Among cancer patients, 21 had solid tumor and 7 had hematologic malignancies. Nine patients (32%) had active malignancy at the time of PMVR. The mean short-term risk score of the patients was similar in the two groups, as were both 30-day and 1-year mortality rates (7% vs. 4%, P = 0.52) and (29% vs. 16%, P= 0.13), respectively. Conclusion: PMVR in cancer patients is associated with similar 30-day and 1 -year survival rate compared with patients without cancer. PMVR should be considered for cancer patients presenting with HF and severe MR and despite their malignancy. This approach may allow cancer patients to safely receive planned oncological treatment.

Original languageAmerican English
Pages (from-to)140-143
Number of pages4
JournalIsrael Medical Association Journal
Issue number3
StatePublished - Mar 2022

Bibliographical note

Publisher Copyright:
© 2022 Israel Medical Association. All rights reserved.


  • Heart Failure/therapy
  • Heart Valve Prosthesis Implantation/adverse effects
  • Humans
  • Mitral Valve Insufficiency/complications
  • Mitral Valve/surgery
  • Neoplasms/complications
  • Treatment Outcome


Dive into the research topics of 'Percutaneous Mitral Valve Repair in Cancer Patients with Heart Failure and Severe Mitral Regurgitation'. Together they form a unique fingerprint.

Cite this